Фармакоэкономическая оценка различных вариантов лечения респираторного дистресс-синдрома новорожденных

Abstract

The treatment strategy for neonatal respiratory distress syndrome (NRDS) includes several options such as early prescription of surfactants, prescription “on demand” using different methods of their administration. A pharmacoeconomic evaluation of various NRDS treatment options was performed using a budget impact analysis according to an appropriate pharmacoeconomic model. The pharmacoeconomic model was based on the results of clinical trials in terms of the risks factors for the most significant complications of NRDS. The model also considered all relevant costs for the national health care system associated with prescribing surfactant therapy. Conclusion. A pharmacoeconomic evaluation of NRDS treatment using the example of two hypothetical cohorts of patients at gestational age of 29 and 32 weeks showed that early surfactant prescription (using Poractant alfa as an example) by Less Invasive Surfactant Administration (LISA) procedure in patients with FiO2 ≥0.3 is strongly preferable in comparison with Continuous Positive Airway Pressure (CPAP) therapy, reducing the mortality rate (by 0.69%), the incidence of life-threatening complications (bronchopulmonary dysplasia, severe intraventricular hemorrhage, and air leak syndrome), as well as providing cost savings to the healthcare system. Key words: poractant alfa, early administration, neonatal respiratory distress syndrome, surfactant